Business Segments · Cost of revenues
Business Segments — Cost of revenues
Neurocrine Biosciences Business Segments — Cost of revenues decreased by 21.6% to $13.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 50.0%, from $9.20M to $13.80M. Over 3 years (FY 2022 to FY 2025), Business Segments — Cost of revenues shows an upward trend with a 31.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Cost of Revenue
How to read this metric
A decrease relative to revenue suggests improved manufacturing efficiency or favorable product mix.
Detailed definition
Includes the direct costs associated with manufacturing, packaging, and distributing the company's pharmaceutical produc...
Peer comparison
Varies by drug type and manufacturing complexity; typically benchmarked as a percentage of total revenue.
Metric ID:
nbix_segment_reportable_segment_cost_of_revenuesHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.80M | $5.80M | $5.80M | $5.80M | $9.93M | $9.93M | $9.93M | $9.93M | $7.50M | $9.20M | $8.00M | $9.30M | $9.20M | $11.30M | $14.00M | $17.60M | $13.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +71.1% | +0.0% | +0.0% | +0.0% | -24.4% | +22.7% | -13.0% | +16.3% | -1.1% | +22.8% | +23.9% | +25.7% | -21.6% |
| YoY Change | — | — | — | — | +71.1% | +71.1% | +71.1% | +71.1% | -24.4% | -7.3% | -19.4% | -6.3% | +22.7% | +22.8% | +75.0% | +89.2% | +50.0% |
Range$5.80M – $17.60M
CAGR+24.2%
Avg YoY Growth+37.4%
Median YoY Growth+50.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — cost of revenues?
- Neurocrine Biosciences (NBIX) reported business segments — cost of revenues of $13.80M in Q1 2026.
- How has Neurocrine Biosciences's business segments — cost of revenues changed year-over-year?
- Neurocrine Biosciences's business segments — cost of revenues increased by 50.0% year-over-year, from $9.20M to $13.80M.
- What is the long-term trend for Neurocrine Biosciences's business segments — cost of revenues?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — cost of revenues has grown at a 31.0% compound annual growth rate (CAGR), from $23.20M to $52.10M.
- What does business segments — cost of revenues mean?
- The direct costs incurred to produce and sell the company's products.